Latest News From Exec Edge

Aug-20	AIR Global Reports 1H Revenue & Gross Profit Growth, Maintains 2026 Guidance AIIR -6.45% AIIR +6.75% Exec Edge
Aug-19	Real Parkinson's Disease Hope from Jupiter Neurosciences JUNS -5.14% Exec Edge
Aug-18	Amer Sports Shares Up After Strong 2Q Performance, Raises 2026 Guidance AS Exec Edge
Aug-17	Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies FULC Exec Edge
Aug-17	Midera Food's Net Sales Up 13%, Raises 2026 Outlook MFP Exec Edge
Aug-12	National Vision Raises Outlook as Higher-Value Customers Fuel Breakout Quarter EYE -11.56% Exec Edge
Aug-06	Once Upon a Farm Lifts 2026 Outlook Again as Q2 Revenue Surges 42% OFRM Exec Edge
Aug-06	Shift4 Q2 Revenue Surges 34%, Adjusts 2026 Outlook FOUR -18.77% Exec Edge
Aug-06	Krispy Kreme Posts 43% EBITDA Growth as Turnaround Gains Momentum DNUT Exec Edge
Aug-06	IQVIA, Medera Partner to Accelerate Development of Cardiac Gene Therapies IQV Exec Edge
Aug-06	Corpay's Price Target Raised by Brokers After Earnings Beat CPAY Exec Edge
Aug-05	a.k.a. Brands 2Q Gross Margin Improves as Fashion Turnaround Gains Momentum AKA Exec Edge
Aug-05	Portillo's 2Q Revenue Climbs, Teases New Long-Term Growth Strategy PTLO PTLO -6.21% Exec Edge
Aug-05	The ONE Group 2Q Operating Income Jumps on Vibe Dining Strength STKS Exec Edge
Aug-05	Tanger Posts Higher Earnings, Raises Dividend as Open-Air Retail Momentum Builds SKT Exec Edge
Aug-04	Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2 SUJA Exec Edge
Jul-15	Acumen Pharmaceuticals Shows Early Alzheimer's Disease Insights ABOS -12.25% Exec Edge
Jul-13	The New Cyber Front Line: Pax8 Corporate VP Oguo Atuanya, CrowdStrike VP Daniel Danielli, Live from Pax8 Beyond 2026 CRWD CRWD +12.14% Exec Edge
Jul-08	Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM GCTK GCTK +6.12% Exec Edge
Jul-06	The Cancer Therapy Strategy VERAXA Is Betting the Company On VRXA +7.35% VRXA +38.36% Exec Edge
Jul-02	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology CDNA Exec Edge
Jul-02	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone VRXA +18.26% VRXA +7.35% Exec Edge
Jun-30	Tackling the AI Security Crisis: Pax8's Rob Belgrave and SentinelOne's Steve Stone, Live from Pax8 Beyond 2026 S Exec Edge

Latest News From Exec Edge

Upgrade your Finviz experience